LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook
LifeStance delivered Q2 revenue of $435.4 million, up 26% year-over-year, driven by higher visit volumes and improved clinician productivity. The company achieved positive net income of $23.6 million and generated $87.9 million in free cash flow, prompting management to raise full-year revenue and Adjusted EBITDA guidance.
Key figures
- Eps
- 0.06
- Revenue
- $435.4 million
- Guidance
- FY26 revenue $1.685B-$1.725B (raised), Adj EBITDA $215M-$235M (raised); Q3 revenue $420M-$440M
- Revenue Yoy
- 26%
- Net income
- 23600000
- Center margin
- 153000000
- Free cash flow
- 87900000
- Adjusted ebitda
- 66000000
- Clinician count
- 8542
- Buyback authorization
- 100000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.